Fair Value Please, page-264

Good read on MSB thread

https://hotcopper.com.au/threads/cell-therapy-news-articles.3765963/page-567?post_id=39953425

Puts GvHD at US$735m sales globally by 2024.
Fuji had forecast capturing US$300m of that by around 2026.

"Therapeutic approaches employing whole cells are not new—for example, techniques based on cultured autologous epidermal cells for burn treatment and chondrocytes for knee cartilage repair have been available for more than a decade. Gene therapy and other gene transcription and translation-targeted approaches such as RNA inter- ference (RNAi) are a much more recent addition to the therapeutic arsenal, and coupled with the high-profile arrival of chimeric antigen receptor (CAR)-T cells are ushering in a new era for cell-based and gene-based medicine.

These groundbreaking scientific advances have also brought with them intense debate about payment models and affordability, add- ing fuel to the broader fire raging around drug pricing. Nonetheless, sell-side consensus forecasts from Evaluate Pharma project growth of the combined cell, gene and nucleic acid therapy market from

$1 billion in 2017 to $44 billion in 2024, resulting in a staggering 65% compound annual growth rate (Fig. 1). With such value at stake, this has been—and will likely continue to be—one of the most keenly watched pharma segments for business development groups and industry observers alike in the next few years."